WO2023161854 - IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOF
National phase entry:
Publication Number
WO/2023/161854
Publication Date
31.08.2023
International Application No.
PCT/IB2023/051688
International Filing Date
23.02.2023
Title **
[English]
IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOF
[French]
IMMUNOCYTOKINES IL-18 SPÉCIFIQUES D'UN ANTIGÈNE IMMUN ET LEURS UTILISATIONS
Applicants **
BRIGHT PEAK THERAPEUTICS AG
Inventors
PATTABIRAMAN, Vijaya Raghavan
KREFT, Bertolt
CARRALOT, Jean-Philippe
GOEPFERT, Arnaud
MARTIN, Kea
CHI, Andrew
Priority Data
63/313,222
23.02.2022
US
63/479,529
11.01.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3951 | |
| EPO | Filing, Examination, Granting | 21913 | |
| Japan | Filing, Examination, Granting | 2738 | |
| South Korea | Filing, Examination, Granting | 3421 | |
| USA | Filing, Examination, Granting | 8290 |
Total:
40,313
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to modified immunocytokine compositions comprising antibodies or antigen binding fragments specific for immune cell antigens and IL-18 polypeptides. Also provided herein are methods of treatment with and methods of manufacture of immunocytokine compositions.[French]
La présente divulgation concerne des compositions d'immunocytokine modifiées comprenant des anticorps ou des fragments de liaison à l'antigène spécifiques d'antigènes de cellules immunitaires et des polypeptides d'IL-18. La divulgation concerne également des méthodes de traitement et des méthodes de fabrication de compositions d'immunocytokine.